A process for the purification of 5-aminosalicylic acid (5-ASA) comprising the steps of: i) preparing an aqueous solution or suspension of 5-ASA, optionally added with at least another solvent; ii) adding a base until reaching a pH between 6 and 9; iii) adding an acid to the solution obtained from step ii) until reaching a pH between 3.2 and 5.2, preferably between 4.3 and 4.6, with consequent precipitation of 5-ASA; iv) separating the precipitated 5-ASA from step iii).
A manufacturing process to produce Linaclotide and its acetate salt, more particularly, to obtain amorphous High-Purity Linaclotide or its acetate salt with a chromatographic purity equal to or higher than 99.9% and a content of IMD-Linaclotide and Cys-1-α-ketone-Linaclotide impurities each one lower than 100 ppm, preferably lower than 50 ppm, more preferably lower than 40 ppm. The invention further relates to an analytical method able to detect IMD-Linaclotide and Cys-1-α-ketone Linaclotide even at 40 ppm level (LOD) and quantify IMD-Linaclotide and Cys-1-α-ketone Linaclotide even at 50 ppm level (LOQ), by Ion-Pairing Chromatography (IPC).
C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
C07C 51/41 - Préparation de sels d'acides carboxyliques par conversion de ces acides ou de leurs sels en sels ayant la même partie acide carboxylique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
3.
PROCESS FOR THE PURIFICATION OF 5-AMINOSALICYLIC ACID
The object of tire present invention is a processfor the purification of 5-ASA. This process allows to obtain a product having a lower content of impurities and in an increased yield.
The object of the present invention is a process for the purification of 5-ASA. This process allows to obtain a product having a lower content of impurities and in an increased yield.
The present invention relates to a manufacturing process to produce Linaclotide and its acetate salt, more particularly, to obtain amorphous High-Purity Linaclotide or its acetate salt with a chromatographic purity equal to or higher than 99.9% and a content of IMD-Linaclotide and Cys-1-a-ketone-Linaclotide impurities each one lower than 100 ppm, preferably lower than 50 ppm, more preferably lower than 40 ppm. The invention further relates to an analytical method able to detect IMD-Linaclotide and Cys-1-a-ketone Linaclotide even at 40 ppm level (LOD) and quantify IMD- Linaclotide and Cys-1-o-ketone Linaclotide even at 50 ppm level (LOQ), by Ion- Pairing Chromatography (IPC).
The present invention relates to a manufacturing process to produce Linaclotide and its acetate salt, more particularly, to obtain amorphous High-Purity Linaclotide or its acetate salt with a chromatographic purity equal to or higher than 99.9% and a content of IMD-Linaclotide and Cys-1-a-ketone-Linaclotide impurities each one lower than 100 ppm, preferably lower than 50 ppm, more preferably lower than 40 ppm. The invention further relates to an analytical method able to detect IMD-Linaclotide and Cys-1-a-ketone Linaclotide even at 40 ppm level (LOD) and quantify IMD- Linaclotide and Cys-1-o-ketone Linaclotide even at 50 ppm level (LOQ), by Ion- Pairing Chromatography (IPC).
The object of the present invention is an anti-xylan sulfate antiserum having an antibody titre of between 1/10000 and 1/15000, and obtainable using a specific immunization method, and use thereof in one or more ELISA methods for determining xylan sulfate levels in biological fluids.
C07K 16/06 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux provenant de sérum
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products, more precisely anticoagulant
products based on enoxaparin sodium used for the pre- and
postoperative prophylaxis of venous thromboembolic diseases,
associated to operations of general surgery, orthopaedic and
cancer surgery, prophylaxis and treatment of deep vein
thrombosis (DVT); anticoagulants.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals, specifically anticoagulants based on enoxaparin sodium for use in pre and post-surgery prophylactic treatment of venous thromboembolic diseases, associated with general surgery, orthopaedic and cancer operations, prophylaxis and treatment of deep vein thrombosis (DVT); Anticoagulants.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals, specifically anticoagulants based on enoxaparin sodium for use in pre and post-surgery prophylactic treatment of venous thromboembolic diseases, associated with general surgery, orthopaedic and cancer operations, prophylaxis and treatment of deep vein thrombosis (DVT); Anticoagulants.
11.
ANTI-XYLAN SULFATE POLYCLONAL ANTISERUM AND USE THEREOF IN ELISA METHODS
The object of the present invention is an anti-xylan sulfate antiserum having an antibody titre of between 1/10000 and 1/15000, and obtainable using a specific immunization method, and use thereof in one or more ELISA methods for determining xylan sulfate levels in biological fluids.
A method for the qualification and selection of manufacturing processes, raw materials, intermediates and batch production of pentosan polysulfate based on the identification of acetylated monosaccharide units, including units of xylose substituted with 4-O-methyl-glucuronic which also lead the acetyl group, as structural characterizing units, is disclosed.
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
G01N 24/08 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance magnétique nucléaire
13.
ANTI-XYLAN SULFATE POLYCLONAL ANTISERUM AND USE THEREOF IN ELISA METHODS
The object of the present invention is an anti-xylan sulfate antiserum having an antibody titre of between 1/10000 and 1/15000, and obtainable using a specific immunization method, and use thereof in one or more ELISA methods for determining xylan sulfate levels in biological fluids.
A process for the purification of L-α-glycerophosphorylcholine is described, wherein L-α-glycerophosphorylcholine is crystallized from DMSO or from a mixture of DMSO with at least another solvent, preferably selected from water, alcohol, halogenated solvents, ethers, esters and/or amides. Such a process allows to obtain L-α-glycerophosphorylcholine having a purity greater than 99.5%, preferably greater than 99.7%, even more preferably greater than or equal to 99.9%. A method for determining the purity of L-α-glycerophosphorylcholine is also described, comprising the elution of L-α-glycerophosphorylcholine through an HPLC column having an amino stationary phase, and subsequent detection of L-α-glycerophosphorylcholine itself, and any impurity thereof, by means of an Evaporative Light Scattering Detector type.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products, more precisely anticoagulant
products based on enoxaparin sodium used for the pre- and
postoperative prophylaxis of venous thromboembolic diseases,
associated to operations of general surgery, orthopaedic and
cancer surgery, prophylaxis and treatment of deep vein
thrombosis (DVT); anticoagulants.
1 group on the same saccharide unit is defined as G, wherein G is hydrogen or acetyl, and wherein the sugar unit at the reducing end of sun such polysaccharide is xylose, lyxose or xylulose, said process comprising the following steps: selective deacetylation of xylan extracted from beech wood; and isomerization of the selectively deacetylated xylan achieved in step or the following steps: isomerization of xylan extracted from beech wood; and selective deacetylation of isomerized xylan achieved in step. The process is useful for the preparation of pentosan polysulfate or pharmaceutically acceptable salts thereof for pharmaceutical use.
The present invention relates to reversed phase high-performance liquid chromatography (HPLC) methods useful for the characterisation of glatiramer acetate or similar polypeptide mixtures. The method described herein can distinguish glatiramer acetate from non-conforming copolymers and may be used to choose batches of glatiramer acetate suitable for pharmaceutical use.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
B01D 15/32 - Chromatographie en phase liée, p. ex. avec une phase normale liée, une phase inverse ou une interaction hydrophobe
G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes
G01N 33/94 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des narcotiques
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
18.
Analysis of the molecular weight distribution of complex polypeptide mixtures
The present invention relates to simple size exclusion chromatography (SEC) analytical methods useful for the assessment of accurate molecular weight distributions (MWDs) of certain polypeptide mixtures known as glatiramoids. The use of a SEC method based on one or more broad MWD standards furnishes the absolute (not relative) molecular weight distribution profile of complex polypeptide mixtures like, for instance, the glatiramer acetate (GA) polymer.
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The present invention relates to a process for the preparation of a polysaccharide composed of D-xylose units of formula (III) linked together via beta 1,4 glycosidic bonds wherein R1 is hydrogen or acetyl, R2 is hydrogen, acetyl or a 4-O-methyl glucuronic acid unit, wherein, when R2 is a 4-O-methyl glucuronic acid unit, the R1 group on the same saccharide unit is defined as G, wherein G is hydrogen or acetyl, and wherein the sugar unit at the reducing end of such polysaccharide is xylose, lyxose or xylulose, said process comprising the following steps: selective deacetylation of xylan extracted from beech wood; and isomerization of the selectively deacetylated xylan achieved in step or the following steps: isomerization of xylan extracted from beech wood; and selective deacetylation of isomerized xylan achieved in step. The process is useful for the preparation of pentosan polysulfate or pharmaceutically acceptable salts thereof for pharmaceutical use.
The present invention relates to a process for the preparation of a polysaccharide composed of D-xylose units of formula (III) linked together via beta 1,4 glycosidic bonds wherein R1 is hydrogen or acetyl, R2 is hydrogen, acetyl or a 4-O-methyl glucuronic acid unit, wherein, when R2 is a 4-O-methyl glucuronic acid unit, the R1 group on the same saccharide unit is defined as G, wherein G is hydrogen or acetyl, and wherein the sugar unit at the reducing end of such polysaccharide is xylose, lyxose or xylulose, said process comprising the following steps: selective deacetylation of xylan extracted from beech wood; and isomerization of the selectively deacetylated xylan achieved in step or the following steps: isomerization of xylan extracted from beech wood; and selective deacetylation of isomerized xylan achieved in step. The process is useful for the preparation of pentosan polysulfate or pharmaceutically acceptable salts thereof for pharmaceutical use.
A method for the qualification and selection of manufacturing processes, raw materials, intermediates and batch production of pentosan polysulfate based on the identification of acetylated monosaccharide units, including units of xylose substituted with 4-O-methyl-glucuronic which also lead the acetyl group, as structural characterizing units, is disclosed.
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
G01N 24/08 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance magnétique nucléaire
22.
PROCESS FOR THE PURIFICATION OF L-.ALPHA.-GLYCEROPHOSPHORYLCHOLINE
A process for the purification of L-a-glycerophosphorylcholine is described, wherein L-a-glycerophosphorylcholine is crystallized from DMSO or from a mixture of DMSO with at least another solvent, preferably selected from water, alcohol, halogenated solvents, ethers, esters and/or amides. Such a process allows to obtain L-a-glycerophosphorylcholine having a purity greater than 99.5%, preferably greater than 99.7%, even more preferably greater than or equal to 99.9%. A method for determining the purity of L-a-glycerophosphorylchoiine is also described, comprising the elution of L-a-glycerophosphorylcholine through an HPLC column having an amino stationary phase, and subsequent detection of L- a-glycerophosphorylcholine itself, and any impurity thereof, by means of an Evaporative Light Scattering Detector type.
A process for the purification of L-α-glycerophosphorylcholine is described, wherein L-α-glycerophosphorylcholine is crystallized from DMSO or from a mixture of DMSO with at least another solvent, preferably selected from water, alcohol, halogenated solvents, ethers, esters and/or amides. Such a process allows to obtain L-α-glycerophosphorylcholine having a purity greater than 99.5%, preferably greater than 99.7%, even more preferably greater than or equal to 99.9%. A method for determining the purity of L-α-glycerophosphorylchoiine is also described, comprising the elution of L-α-glycerophosphorylcholine through an HPLC column having an amino stationary phase, and subsequent detection of L- α-glycerophosphorylcholine itself, and any impurity thereof, by means of an Evaporative Light Scattering Detector type.
The present invention relates to a new process for the synthesis of Colesevelam, which is used in therapy in cases of hypercholesterolemia due to low density lipoproteins. Said process comprises the reaction, in a basic environment, of polyallylamine with: i) at least one alkylating agent of formula X-(CH2)9-CH3 and at least one alkylating agent of formula Y-(CH2)6-N+ (CH3)3Z-, wherein X and Y are each independently a leaving group, and Z is a halogen; and ii) at least one crosslinking agent. The present invention also relates to the Colesevelam obtainable by the above process.
C08F 8/00 - Modification chimique par post-traitement
C08F 8/30 - Introduction d'atomes d'azote ou de groupes contenant de l'azote
C08F 8/44 - Préparation de sels métalliques ou de sels d'ammonium
C08F 226/02 - Copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par une liaison simple ou double à l'azote ou par un hétérocycle contenant de l'azote par une simple ou une double liaison à l'azote
An analytical method for the structural determination of polysaccharides, especially glycosaminoglycans (GAGs) such as heparin (RN=9005-49-6) is described which comprises the use of a mass spectrometer optionally coupled with a chromatographic or electrophoretic system. In a preferred embodiment, reverse phase ion pair HPLC is used to separate an enzyme digest of the polysaccharide and the fractions are analysed via ESI-QTOF mass spectrometry. In particular, a highly charged precursor ion (PI), which is resistant to S03 loss, is selected and subjected to collisional dissociation (CID), whereby the structure can be identified by the presence of characteristic fragment peaks at m/z 137.99, 138.97, 168.49, 157.01, 189.49... 369.10 etc. Applications include quality control of pharmaceutical products.
G01N 33/66 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les sucres du sang, p. ex. le galactose
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
New formulations of bendamustine hydrochloride having HPLC purity higher than 99% obtained through the lyophilization of aqueous solutions without organic solvents, are described.
A method for the qualification and selection of manufacturing processes, raw materials, intermediates and batch production of pentosan polysulfate based on the identification of acetylated monosaccharide units, including units of xylose substituted with 4-O-methyl-glucuronic which also lead the acetyl group, as structural characterizing units, is disclosed.
Bortezomib esters with tartaric acid wherein the molar ratio between bortezomib and tartaric acid is 2:1 and formulations containing them are described.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products namely pharmaceutical preparations
for the treatment of neoplastic hyper-calcemia and for
prevention of events related to the skeletal system in
patients with malignant cancers at an advance stage
involving bone; pharmaceutical and veterinary preparations;
food for babies; plasters, materials for dressings; material
for stopping teeth and dental wax; disinfectants;
preparations for destroying vermin; fungicides, herbicides.
A process for the preparation of a prodrug of 5-aminosalicylic acid, namely 2-butanoyloxy-5-amino-benzoic acid,and solid forms of such compound are described.
C07C 227/04 - Formation de groupes amino dans des composés contenant des groupes carboxyle
C07C 229/64 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé le squelette carboné étant substitué de plus par des atomes d'oxygène liés par des liaisons simples
31.
Polymorph of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2-naphthalenyl) ester
Herein described is a novel crystalline form of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2-naphtalenyl) ester. In particular, herein described is a polymorph of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2-naphtalenyl) ester, characterized by a Powder X Ray Diffraction spectrum as indicated in FIG. 1, and/or by a DSC profile as indicated in FIG. 2, and/or by a TGA profile as indicated in FIG. 3 and/or by an IR spectrum as indicated in FIG. 4.
A01N 37/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques
A61K 31/21 - Esters, p. ex. nitroglycérine, sélénocyanates
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical products; More precisely anti-thrombotic specialist pharmaceuticals for treating peripheral arteriopathy (including obliterant peripheral arteriopathy), treating chronic arterial ischemia and treatment of peripheral vascular diseases which are secondary to systemic diseases; Veterinary and sanitary preparations; Baby food; Plasters, materials for dressings; Material for stopping teeth and for dental impressions; Disinfectants; Preparations for destroying vermin; Fungicides; Herbicides.
Machines and machine tools, motors (except for land vehicles). Surgical and medical apparatus and instruments,In particular infusion pumps for administering medication.
34.
PROCESS FOR THE PREPARATION OF 2 -HYDROXY- 4 -PHENYL -3, 4 -DIHYDRO-2H-CHROMEN- 6 -YL -METHANOL AND (R) - FESO - DEACYL
The present invention regards an improved and industrially advantageous process for the preparation of the 2-hyaroxy-4-phenyl-3,4-dihydro-2H-chromen-6-yl-methanol intermediates, also called "feso chromenyl" and (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenol, also called "(R)-feso deacyl", which are in turn used in the synthesis of fesoterodine and in particular of fesoterodine furnarate. This process utilises reagents which are non-toxic and manageable at industrial level and enables obtaining a new stable and non-hygroscopic crystalline form of the key intermediate "(R)-feso deacyl", called form B.
C07D 311/20 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 2 hydrogénés dans l'hétérocycle
C07C 215/54 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino reliés au cycle aromatique à six chaînons, ou au système cyclique condensé contenant ce cycle par l'intermédiaire de chaînes carbonées qui ne sont pas substituées de plus par des groupes hydroxy reliés par l'intermédiaire de chaînes carbonées ayant au moins trois atomes de carbone entre les groupes amino et le cycle aromatique à six chaînons ou le système cyclique condensé contenant ce cycle
C07C 219/28 - Composés contenant des groupes amino et hydroxy estérifiés liés au même squelette carboné ayant des groupes hydroxy estérifiés liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques du squelette carboné
35.
Process for the synthesis of azacitidine and decitabine
Described herein is a process for the synthesis of azacitidine or decitabine, comprising the silylation of azacytosine in the presence of N,O-bis-trimethylsilyl-trifluoroacetamide. Such reaction is performed in an organic solvent, preferably aprotic, even more preferably selected from among dichloromethane, dichloroethane and/or acetonitrile. According to a further aspect of the process, 2 to 3 moles of N,O-bis-trimethylsilyl-trifluoroacetamide are used per mole of azacytosine, preferably from 2.2 to 2.5.
C07H 1/00 - Procédés de préparation des dérivés du sucre
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
36.
NOVEL POLYMORPH OF THE HYDROCHLORIDE OF THE (4-HYDROXYCARBAMOYL-PHENYL)-CARBAMIC ACID (6-DIMETHYLAMINO METHYL-2-NAPHTALENYL) ESTER
Herein described is a novel crystalline form of the hydrochloride of the (4- hydroxycarbamoyl-pheny3)-carbamic acid (6-dimethylamino methyl-2- naphtalenyl) ester. In particular, herein described is a polymorph of the hydrochloride of the (4- hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2- naphtalenyl) ester, characterized by a Powder X Ray Diffraction spectrum as indicated in Figure 1, and/or by a DSC profile as indicated in figure 2, and/or by a TGA profile as indicated in figure 3 and/or by an IR spectrum as indicated in figure 4.
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
37.
NOVEL POLYMORPH OF THE HYDROCHLORIDE OF THE (4-HYDROXYCARBAMOYL-PHENYL)-CARBAMIC ACID (6-DIETHYLAMINO METHYL-2-NAPHTHALENYL) ESTER
Herein described is a novel crystalline form of the hydrochloride of the (4-hydroxycarbamoyl-pheny3)-carbamic acid (6-diethylamino methyl-2- naphtalenyl) ester. In particular, herein described is a polymorph of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylamino methyl-2- naphtalenyl) ester, characterized by a Powder X Ray Diffraction spectrum as indicated in Figure 1, and/or by a DSC profile as indicated in figure 2, and/or by a TGA profile as indicated in figure 3 and/or by an IR spectrum as indicated in figure 4.
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
38.
Process for the production of N-acyl-phosphatidyl-ethanolamine
30, pure or mixed together, and X═OH or OM, where M=alkaline metal or alkaline earth, ammonium or alkylammonium. The process in question allows the conversion of lecithin of synthetic or natural origin into N-Acyl-Phosphatidyl-Ethanolamine of formula (I) of high purity, using a limited molar excess of the reagent N-acyl-ethanolamine, where the acyl is as defined above for the formula (I) through reaction of transphosphatidylation in the presence of the enzyme phospholipase D and in conditions suitable for production on an industrial scale.
Described is a new process for producing temozolomide, comprising the reaction between 5-aminoimidazole-4-carboxamide and N-succinimidyl-N′-methyl carbamate and the subsequent reaction of the thus obtained carbamoyl 5-aminoimidazole-4-carboxamide with sodium nitrite. Temozolomide is then purified by chromatography on adsorbent polymeric resin and subsequent crystallization from water and acetone.
C07D 233/66 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
40.
PROCESS FOR THE PRODUCTION OF N-ACYL-PHOSPHATIDYL-ETHANOLAMINE
The document describes a process for the preparation of N-Acyl-Phosphatidyl-Ethanolamine of formula (I) on an industrial scale, In which R1, R2 and R3 are, independently from each other, saturated, monounsaturated or polyunsaturated acyls C1O-C30, pure or mixed together, and X=OH or OM, where M= alkaline metal or alkaline earth, ammonium or alkylammonium. The process in question allows the conversion of lecithin of synthetic or natural origin into N-Acyl-Phosphatidyl-Ethanolamine of formula (I) of high purity, using a limited molar excess of the reagent N-acyl-ethanolamine, where the acyl is as defined above for the formula (I) through reaction of transphosphatidylation in the presence of the enzyme phospholipase D and in conditions suitable for production on an industrial scale.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Produits pharmaceutiques, vétérinaires et hygiéniques;
substances diététiques à usage médical, aliments pour bébés;
emplâtres, matériel pour pansements; matières pour plomber
les dents et pour empreintes dentaires; désinfectants;
produits pour la destruction des animaux nuisibles;
fongicides, herbicides.
